Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04)
University of Michigan Rogel Cancer Center
University of Michigan Rogel Cancer Center
Incyte Corporation
Eli Lilly and Company
Peking University
Mayo Clinic
Medical University of South Carolina
University of Alabama at Birmingham
Taiho Oncology, Inc.
QED Therapeutics, a BridgeBio company
Academic and Community Cancer Research United
EpicentRx, Inc.
EMD Serono
University of Texas Southwestern Medical Center
Merck Sharp & Dohme LLC
NuCana plc
TerSera Therapeutics LLC
Incyte Corporation
The First Affiliated Hospital with Nanjing Medical University
Boston Scientific Corporation
National Cancer Institute (NCI)
ASLAN Pharmaceuticals
Gilead Sciences
American College of Radiology Imaging Network
UNICANCER
Memorial Sloan Kettering Cancer Center
Johannes Gutenberg University Mainz
Concordia Laboratories Inc.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Allina Health System
Georgetown University
King Faisal Specialist Hospital & Research Center
Centre Hospitalier Universitaire de Besancon
New Mexico Cancer Research Alliance
AIO-Studien-gGmbH
University Hospital Tuebingen
NYU Langone Health
Masonic Cancer Center, University of Minnesota
Chinese University of Hong Kong
Peking University
Hoffmann-La Roche
European Organisation for Research and Treatment of Cancer - EORTC
Emory University
Japan Clinical Oncology Group
Stanford University
University of Michigan Rogel Cancer Center
AstraZeneca
Amgen
Amgen
University Hospital, Gasthuisberg